Live online and onsite in Würzburg!
Dear colleagues!
Fortunately, the treatment landscape for aggressive lymphoma has undergone a revolution in the last few years. Current therapies have had an impact on first-line therapy. Immunotherapies such as CAR T-cells and bispecific antibodies are now used as standard of care from the second line onwards. As a result more and more colleagues are using these therapeutic options and thus generating a broad knowledge of the effectiveness and side effects of these therapies. With our DLBCL congress we are happy to offer a platform where we all can exchange and develop ideas with colleagues and learn from each other.
Whether on site in Würzburg or live online: we are looking forward to a highly informative and exciting event and a lively exchange with you!
Best regards,
Johannes Düll
Senior physician
Universitätsklinik Würzburg
An event of:
Academy2 GmbH & Co. KG
Fürther Straße 33
90513 Zirndorf, Germany
events@academy2.de
Mit dem CMEducation.de-Newsletter erhalten Sie regelmäßige Informationen zu neuen Veranstaltungen von CMEducation.de
